Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against Aspergillus and Candida isolates - 13/08/20

Doi : 10.1016/j.mycmed.2020.101014

Z. Sadeghi-Ghadi ^a, A. Vaezi ^b, F. Ahangarkani ^c,^d, M. Ilkit ^e, P. Ebrahimnejad ^f,^g,⁎, ^{^{1
Pedram Ebrahimnejad and Hamid Badali have contributed equally to this work.}} , H. Badali ^b,⁎, ^d,^h,^{^{1
Pedram Ebrahimnejad and Hamid Badali have contributed equally to this work.}}
^a Department of Pharmaceutics, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran
^b Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
^c Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
^d Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran
^e Division of Mycology, Department of Microbiology, Faculty of Medicine, University of Çukurova, Adana, Turkey
^f Pharmaceutical Science Research Center, hemoglobinopathy institute, Mazandaran University of Medical Sciences, Sari, Iran
^g Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
^h Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA

^⁎Corresponding authors.

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Thursday 13 August 2020
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

The rapid emergence of resistance to classical antifungals has increased the interest in novel antifungal compounds. Curcumin and quercetin are two natural plant-derived bioactive molecules shown to promote wound healing in injured tissues. In this study, we investigated the in vitro susceptibility of several Aspergillus and Candida isolates to curcumin and quercetin encapsulated in nanovesicles with and without hyaluronan and elucidated the efficacy of these nanovesicles as topical drug delivery systems. Antifungal susceptibility testing performed according to the CLSI guidelines indicated that curcumin-quercetin co-encapsulated in nanovesicles without hyaluronan (CUR-QUE-NV-WH) had stronger activity against Candida isolates than fluconazole. Furthermore, CUR-QUE-NV-WH showed efficacy against fluconazole-resistant Candida isolates as evidenced by MICs at least two times lower than those of fluconazole. Examination of skin permeation profiles using an in vitro Franz diffusion cell system revealed that curcumin and quercetin delivered by nanovesicles were released and accumulated in the skin; however, only quercetin could penetrate through the skin layers. Collectively, our results demonstrate that CUR-QUE-NV-WH has potent antifungal activity against Candida isolates and might be a topical treatment, which warrants its further investigation as a novel antifungal agent.

Le texte complet de cet article est disponible en PDF.

Keywords : Nanovesicle, Curcumin, Quercetin, Antifungal susceptibility testing